✦ LIBER ✦

High-dose superselective intra-arterial cisplatin and concomitant radiation (radplat) for advanced head and neck cancer

✍ Scribed by Alfons J. M. Balm; Coen R. N. Rasch; Jan H. Schornagel; Frans J. M. Hilgers; Ronald B. Keus; Leo Schultze-Kool; Annemieke H. Ackerstaff; Wim Busschers; I. Bing Tan

Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 150 KB
Volume: 26
Category: Article
ISSN: 1043-3074
DOI: 10.1002/hed.20006

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background.

The purpose of this study was to study the effect of intensive targeted chemoradiation in a group of patients with head and neck cancer with stage IV inoperable disease.

Methods.

We examined 79 patients with inoperable stage IV head and neck cancer receiving intra‐arterial infusion of high‐dose cisplatin (150 mg/m^2^) on days 2, 9, 16, and 23 concomitant with delivery of external beam radiotherapy (total dose, 70 Gy; 2 Gy, 35 fractions; 1 fraction/day for 7 weeks). Sodium thiosulfate was administered intravenously to provide effective cisplatin neutralization.

Results.

Four patients were not assessable. Complete local tumor response was achieved in 72 patients (91%) and a partial response in three patients. The complete response rate of neck node metastases was 90%. The 1‐ and 2‐year locoregional control rates were 82% and 69%, respectively. The median overall survival time was 2.2 years, with a 3‐year overall survival probability of 43%. Acute toxicities were as follows: grade III/IV hematologic toxicity (22%/16%), grade III/IV nephrotoxicity (0%), grade III mucositis (43%), grade III skin reactions (24%), grade III toxicity of the upper gastrointestinal tract (57%), grade III nausea (20%), and grade III subjective hearing loss (10%). Grade V toxicity (treatment‐related deaths) was 3.8%. Six (18%) of 33 patients with complete remission needed tube feeding 2 years after treatment without intercurrent salvage surgery.

Conclusions.

Supradose superselective intra‐arterial cisplatin and concomitant radiation is an effective organ‐preserving therapy in an unfavorable group of patients. Our series confirms encouraging results reported previously. This regimen is justified in unresectable patients despite the substantial toxicity. © 2004 Wiley Periodicals, Inc. Head Neck 26: 485–493, 2004

📜 SIMILAR VOLUMES

Rapid superselective high-dose cisplatin

Rapid superselective high-dose cisplatin infusion with concomitant radiotherapy for advanced head and neck cancer

✍ Akihiro Homma; Yasushi Furuta; Fumiyuki Suzuki; Nobuhiko Oridate; Hiromitsu Hata 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

## Purpose: The purpose of this study was to evaluate the efficacy of rapid superselective high-dose cisplatin infusion with concomitant radiotherapy for previously untreated patients with advanced head and neck cancer. ## Methods: Forty-three patients for whom surgery was contraindicated or who

Postoperative reduced dose of cisplatin

Postoperative reduced dose of cisplatin concomitant with radiation therapy in high- risk head and neck squamous cell carcinoma

✍ Giovanni Franchin; Emilio Minatel; Doriano Politi; Carlo Gobitti; Renato Talamin 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 2 views

High-dose cisplatin for locally advanced

High-dose cisplatin for locally advanced or metastatic head and neck cancer. A phase ii pilot study

✍ Kathleen A. Havlin; John G. Kuhn; J. William Myers; Robert F. Ozols; Douglas E. 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 484 KB 👁 2 views

High-dose intra-arterial cisplatin and c

High-dose intra-arterial cisplatin and concurrent hyperfractionated radiation therapy in patients with locally advanced primary squamous cell carcinoma of the head and neck: Report of a phase II study

✍ William F. Regine; Joseph Valentino; William John; Gayle Storey; David Sloan; Da 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 3 views

Accelerated fractionation radiotherapy a

Accelerated fractionation radiotherapy and late intensification with 2 intra-arterial cisplatin infusions for locally advanced head and neck squamous cell carcinoma

✍ Kwok Hung Yu; Simon C. H. Yu; Edwin P. Hui; Michael K. M. Kam; Alexander C. Vlan 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 2 views

## Abstract ## Background This study was established to determine the maximum tolerated dose of intra‐arterial cisplatin (IAC) concurrent with accelerated fractionation radiotherapy for locally advanced head and neck squamous cell carcinoma (HNSCC). ## Methods We conducted a phase I study. Treat

Superselective high-dose cisplatin infus

Superselective high-dose cisplatin infusion with concomitant radiotherapy in patients with advanced cancer of the nasal cavity and paranasal sinuses : A single institution experience

✍ Akihiro Homma; Nobuhiko Oridate; Fumiyuki Suzuki; Shigenari Taki; Takeshi Asano; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 287 KB 👁 1 views

## Abstract ## BACKGROUND: The current study aimed to evaluate the efficacy of superselective high‐dose cisplatin infusion with concomitant radiotherapy (RADPLAT) for previously untreated patients with advanced cancer of the nasal cavity and paranasal sinuses. ## METHODS: Between October 1999 an